Intravenous lidocaine for the treatment of background or procedural burn pain

Simple item page
dc.contributor.authorJason Wasiak
dc.contributor.authorPatrick Mahar
dc.contributor.authorSiobhan McGuinness
dc.contributor.authorAnneliese Spinks
dc.contributor.authorStefan Danilla
dc.contributor.authorHeather Cleland
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T21:05:35Z
dc.date.available2026-03-22T21:05:35Z
dc.date.issued2012
dc.descriptionCitaciones: 18
dc.description.abstractAs current clinical evidence is based on only one single RCT as well as case series and reports, intravenous lidocaine must be considered a pharmacological agent under investigation in burns care, the effectiveness of which is yet to be determined with further well-designed and conducted clinical trials.
dc.identifier.doi10.1002/14651858.cd005622.pub3
dc.identifier.urihttps://doi.org/10.1002/14651858.cd005622.pub3
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/85883
dc.language.isoen
dc.publisherElsevier BV
dc.relation.ispartofCochrane Database of Systematic Reviews
dc.sourceThe Alfred Hospital
dc.subjectMedicine
dc.subjectLidocaine
dc.subjectPlacebo
dc.subjectOpioid
dc.subjectCochrane Library
dc.subjectAnesthesia
dc.subjectClinical trial
dc.subjectBurn injury
dc.subjectRandomized controlled trial
dc.subjectMorphine
dc.titleIntravenous lidocaine for the treatment of background or procedural burn pain
dc.typereview

Files

Collections

Artículo Científico Publicado